Akcea’s Exclusivity Covenants Clause Samples
Akcea’s Exclusivity Covenants are contractual provisions that restrict Akcea from engaging in certain activities with third parties, typically relating to the development, commercialization, or licensing of specific products or technologies covered by the agreement. These covenants may prohibit Akcea from entering into similar agreements with competitors or from working on competing products during the term of the contract. The primary purpose of these covenants is to protect the other party’s interests by ensuring that Akcea’s resources and innovations are dedicated exclusively to the partnership, thereby reducing the risk of conflicts of interest and safeguarding competitive advantages.
Akcea’s Exclusivity Covenants. On a Product-by-Product and Exclusive Target-by-Exclusive Target basis, Akcea and its Affiliates will not (independently or with a Third Party):
Akcea’s Exclusivity Covenants. Akcea, its Affiliates, and its Sublicensees will not work independently or for or with any Third Party (including the grant of any license to any Third Party) with respect to the Development or Commercialization of any product (including an ASO) that (a) is a Competing Product, or (b) is reasonably expected to decrease the market share for a Product and treats or is intended to treat transthyretin amyloidosis or any other Indication for which a Product is being Developed or Commercialized under this Agreement, in each case ((a) and (b)), until, on a Product-by-Product and country-by-country basis, the expiration of the last Valid Claims in an Ionis Patent Covering a Product in a country.
Akcea’s Exclusivity Covenants. On a Product-by-Product and Exclusive Target-by-Exclusive Target basis, Akcea and its Affiliates will not (independently or with a Third Party):
(a) During the Option Period. During the Option Period, grant any license or other right to a Third Party that would diminish Novartis’ rights under Section 3.1 or Section 5.1.1 or Section 5.1.2 (as applicable) or otherwise under this Agreement. Furthermore, for [***] ([***]) months following the Effective Date, unless required to perform its obligations under this Agreement, neither Akcea nor any of its Affiliates shall (independently or with or through any Third Party) solicit, initiate, seek, encourage or support any inquiry, proposal or offer from, furnish any information to, or participate in any discussions or negotiations with any Third Party with respect to any licensing, acquisition or any collaboration or joint venture relating to the research, development or commercialization of any Product.
(b) After the Option Period. After the Option Period, [***], for a period of [***] months after the [***] of such Product [***].